N@N

BioMimetic Therapeutics, Inc. to Report 2011 Third Quarter Financial Results on November 8

^{Published on 2011-11-05 07:56:23 - Market Wire}
 

FRANKLIN, Tenn.--([ BUSINESS WIRE ])--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three and nine months ended September 30, 2011, on Tuesday, November 8 after the close of market. The Company will host a conference call and audio webcast to discuss its third quarter financial results, product development programs and business activities at 4:30 p.m. EST the same day.

The conference call may be accessed on November 8, 2011 by dialing (877) 224 - 4059 for U.S. and Canadian callers (passcode: 24057364). The international dial in number is (706) 902 - 2069, and the same passcode applies. Participants should dial in 10 minutes prior to the call.

A live webcast of the conference call will be available on the Investor Relations section of BioMimeticas website at [ www.biomimetics.com ]. The webcast will be archived for at least 30 days following the call.

About BioMimetic Therapeutics

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.

In May 2011, BioMimeticas Pre-Marketing Approval (PMA) application for Augment Bone Graft received a positive orthopedic advisory panel recommendation on the safety, efficacy and risk profile for the use of the product as an alternative to autograft in hindfoot and ankle fusions and is currently under review by the FDA. Additionally, BioMimetic received regulatory approval in 2009 and 2011 to market the product in Canada and Australia, respectively and is awaiting an approvability decision in Europe, which is expected during the first half of 2012.

For further information, visit [ www.biomimetics.com ] or contact Kearstin Patterson, director of corporate communications, at 615-236-4419.